In the OASIS-4 trial, oral Wegovy (25 mg) demonstrated an average weight loss of approximately 13.6% from baseline at 64 weeks in adults without diabetes
and Inspire Medical Systems Inc., which manufacture such equipment, may see a reduction in demand, with Airfinity projecting a potential market contraction of over 11% in the coming years due to the increased use of weight loss drugs as a therapeutic alternative.
NCT04881760 U.S
Its crucial for patients to understand that while GLP-1 medications are revolutionary tools that accelerate weight lossto reach their goals they still need to make [healthy] lifestyle changes, fix relationships with food, and work on exercise consistency
By bypassing traditional pharmacy networks, PlexusDx reduces overhead costs and passes savings directly to patients seeking effective weight management without the administrative burden of insurance coverage
Special Considerations for Women Over 40 or 50 While semaglutide produces similar results in women regardless of their age, those going through perimenopause or menopause may have additional health concerns to consider namely, the risk of muscle and bone loss
